RXFP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15528521	1.00	1/20
SCHEMBL16670090	1.00	1/20
SCHEMBL15530053	0.86	1/20
SCHEMBL28665241	0.76	1/20
SCHEMBL15528615	0.71	1/20
SCHEMBL6168414	0.69	1/20
SCHEMBL15528295	0.67	1/20
SCHEMBL15529980	0.66	1/20
SCHEMBL15528556	0.65	1/20
SCHEMBL15528361	0.65	1/20
SCHEMBL15528386	0.65	1/20
SCHEMBL15528839	0.65	1/20
SCHEMBL27179950	0.65	1/20
SCHEMBL30926915	0.65	1/20
SCHEMBL15528420	0.64	1/20
SCHEMBL15528482	0.64	1/20
SCHEMBL15528490	0.64	1/20
SCHEMBL15528508	0.64	1/20
SCHEMBL16670177	0.64	1/20
SCHEMBL15528229	0.64	1/20

Clinical trials — most relevant to RXFP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
A Study Of The Usage Of Statins In A Community Heart Failure Population	PHASE4	COMPLETED
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD	PHASE4	UNKNOWN
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure	PHASE2/PHASE3	COMPLETED
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	PHASE3	UNKNOWN
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.	PHASE3	UNKNOWN
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients	PHASE2/PHASE3	UNKNOWN
Role of Colchicine as Anti-Inflammatory Therapy in HFpEF	PHASE3	ACTIVE_NOT_RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities	PHASE2	COMPLETED
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia	PHASE2	RECRUITING
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease	EARLY_PHASE1	RECRUITING
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression	nan	COMPLETED
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus	nan	NOT_YET_RECRUITING
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
The Severe Asthma Research Program III-Boston Clinical Site	nan	COMPLETED
Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure	nan	UNKNOWN
Nutritional Management of Acute and Chronic Enterocutaneous Fistulae	nan	UNKNOWN
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RXFP2 binder may also engage these)

Protein	Name	Similarity
Q5XM32	—	1.000	Q5XM32 →
Q6R6I6	—	0.991	Q6R6I6 →
Q91ZZ5	—	0.991	Q91ZZ5 →
Q5R5V8	—	0.986	Q5R5V8 →
Q6QMG1	—	0.983	Q6QMG1 →
Q6R6I7	—	0.983	Q6R6I7 →
E5DHB5	—	0.982	E5DHB5 →
TSHR	Thyrotropin receptor	0.982	landscape →
RXFP1	Relaxin receptor 1	0.981	landscape →
Q9BGN4	—	0.980	Q9BGN4 →
Q27987	—	0.979	Q27987 →
P21463	—	0.979	P21463 →
LHCGR	Lutropin-choriogonadotropic hormone receptor	0.979	landscape →
P14763	—	0.978	P14763 →
F7D3V9	—	0.978	F7D3V9 →
P47750	—	0.977	P47750 →
P16582	—	0.976	P16582 →
Q5R482	—	0.976	Q5R482 →
Q8SPP9	—	0.976	Q8SPP9 →
B0BLW3	—	0.975	B0BLW3 →
O02721	—	0.975	O02721 →
P56495	—	0.973	P56495 →
Q28585	—	0.973	Q28585 →
Q28005	—	0.973	Q28005 →
Q9Z1P4	—	0.972	Q9Z1P4 →
P58682	—	0.971	P58682 →
D4AC13	—	0.971	D4AC13 →
P0DM44	—	0.970	P0DM44 →
A0N0X6	—	0.970	A0N0X6 →
Q8CBC6	—	0.970	Q8CBC6 →